Antibodies to the ligand for CD40 (CD154) have been shown to exert profound effects on the development of cell-mediated immune responses in mice. The present study shows that an antibody to human CD154 (hCD40L) inhibits in vivo Tetanus toxoid (TT) specific secondary antibody responses in hu-PBL-scid mice, as well as the expansion of xenoreactive human T cells in the scid mice. A possible cause for the reduced expansion of xenoreactive, human T cells, was the decreased expression of murine B7.1 and B7.2 caused by the administration of anti-hCD40L. Therefore, it may be that defective maturation of murine antigen-presenting cells impeded the priming and expansion of human xenoreactive T cells.
BanchereauJ.; BazanF.; BlanchardD.; BriereF.; GalizziJ.P.; van KootenC.; LiuY.J.; RoussetF.; SaelandS.The CD40 antigen and its ligand.Annu. Rev. Immunol.12: 881–922; 1994.
2.
BuhlmannJ.E.; FoyT.M.; AruffoA.; CrassiK.M.; LedbetterJ.A.; GreenW.R.; XuJ.C.; ShultzL.D.; RoopesianD.; FlavellR.A.; FastL.; NoelleR.J.; DurieF.H.In the absence of a CD40 Signal, B Cells Are Tolerogenic.Immunity2: 645–653; 1995.
3.
CarlssonR.; MartenssonC.; KalliomakiS.; OhlinM.; BorrebaeckC.A.Human peripheral blood lymphocytes transplanted into SCID mice constitute an in vivo culture system exhibiting several parameters found in a normal humoral response.J. Immunol.148: 1065–1073; 1992.
ChenF.A.; WilliamsS.S.; FanslowW.C.; BankertR.B.Human antibody response in human peripheral blood leukocyte/severe combined immunodeficient chimeric model is dependent on B and T cell costimulation via CD40/CD40 ligand.J. Immunol.155: 2833–2840; 1995.
6.
de BoerM.; KasranA.; KwekkeboomJ.; WalterH.; VandenbergheP.; CeuppensJ.L.Ligation of B7 with CD28/CTLA-4 on T cells results in CD40 ligand expression, interleukin-4 secretion and efficient help for antibody production by B cells.Eur. J. Immunol.23: 3120–3125; 1993.
7.
DuchosalM.A.; EmingS.A.; McConaheyP.J.; DixonF.J.The hu-PBL-SCID mouse model: Long term human serologic evolution associated with the xenogeneic transfer of human peripheral blood leukocytes into SCID mice.Cell. Immunol.139: 468–477; 1992.
8.
DurieF.H.; AruffoA.; LedbetterJ.A.; CrassiK.M.; GreenW.R.; NoelleR.J.Antibody to the ligand of CD40, gp39, blocks the occurence of the acute and chronic forms of graft-versus-host disease.J. Clin. Invest.94: 1333–1338; 1994.
9.
DurieF.H.; FavaR.A.; FoyT.M.; AruffoA.; LedbetterJ.A.; NoelleR.J.Prevention of collagen- Induced arthritis with an antibody to gp39, the ligand for CD40.Science261: 1328–1330; 1993.
10.
FoyT.; AruffoA.; BajorathJ.; BuhlmannJ.E.; NoelleR.J.Immune regulation by CD40 and its ligand gp39.Annu. Rev. Immunol.14: 591–617; 1996.
11.
FoyT.M.; AruffoA.; LedbetterJ.A.; NoelleR.J.In vivo CD40-gp39 interactions are essential for thymus-dependent immunity. II. Prolonged in vivo suppression of primary and secondary humoral immune responses by an antibody targeted to the CD40 ligand, gp39.J. Exp. Med.178: 1567–1575; 1993.
12.
FoyT.M.; LamanJ.D.; LedbetterJ.A.; AruffoA.; ClaassenE.; NoelleR.J.gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory.J. Exp. Med.180: 157–164; 1994.
13.
GrewalI.S.; XuJ.; FlavellR.A.Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand.Nature378: 617–620; 1995.
14.
HeegK.; WagnerH.Induction of peripheral tolerance to class I major histocompatibility complex (MHC) alloantigens in adult mice: Transfused class I MHC-incompatible splenocytes veto clonal responses of antigen-reactive Lyt-2+ T cells.J. Exp. Med.172: 719–728; 1990.
15.
HesseltonR.M.; GreinerD.L.; MordesJ.P.; RajanT.V.; SullivanJ.L.; ShultzL.D.High levels of human peripheral blood mononuclear cell engraftment and enhanced susceptibility to human immunodeficiency virus type 1 infection in NOD/LtSz-scid/scid mice.J. Infect. Dis.172: 974–782; 1995.
16.
HollenbaughD.; GrosmaireL.; KullasC.D.; ChalupnyN.J.; NoelleR.J.; StamenkovicI.; LedbetterJ.A.; AruffoA.The human T cell antigen gp39, a member of the TNF gene family, is aligand for the CD40 receptor: Expression of a soluble form of gp39 with B cell co-stimulatory activity.EMBO J.11: 4313–4321; 1992.
17.
HollenbaughD.; OchsH.D.; NoelleR.J.; LedbetterJ.A.; AruffoA.The role of CD40 and its ligand in the regulation of the immune response.Immunol. Rev.138: 23–37; 1994.
18.
KawabeT.; NakaT.; YoshidaK.; TanakaT.; FujiwaraH.; SuematsuS.; YoshidaN.; KishimotoT.; KikutaniH.The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation.Immunity1: 167–178; 1994.
19.
KennedyM.K.; MohlerK.M.; ShanebeckK.D.; BaumP.R.; PichaK.S.; Ottene-EvansC.A.; JanewayC.A.; GrabsteinK.H.Induction of B cell costimulatory function by recombinant murine CD40 ligand.Eur. J. Immunol.24: 116–123; 1994.
20.
KreigerJ.L; GrammerS.F.; GreyH.M.; ChestnutR.W.Antigen presentation by splenic B cells: Resting B cells are ineffective, whereas activated B cells are effective accessory cell for T cell responses.J. Immunol.135: 2937–2946; 1995.
21.
KuiperH.M.; BrouwerB.M.; de BoerM.; ParrenP., van LierR.A.Differences in responsiveness to CD3 stimulation between naive and memory CD4+ T cells cannot be overcome by CD28 costimulation.Eur. J. Immunol.24: 1956–1960; 1994.
22.
LarsenC.P.; ElwoodE.T.; AlexanderD.Z.; RitchieS.C.; HendrixR.; TuckerB.C.; ChoH.R.; AruffoA.; HollenbaughD.; LinsleyP.S.; WinnK.J.; PearsonT.C.Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways.Nature381: 434–438; 1996.
23.
McCuneJ.M.; NamikawaR.; KaneshimaH.; SchultzL.D.; WeissmanI.L.The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function.Science241: 1632–1635; 1988.
24.
MishellB.; SkiigiS.M.; HenryC.; ChanE.L.; NorthJ.; GallilyR.; SlomichM.; MillerK.; MarbrookJ.; ParksD.; GoodA.H.Preparation of mouse cell suspensions. In: ShiigiB.M.; ShiigiS.M. eds. Selected methods in cellular immunology.San Francisco: W.H. Freeman and Co.; 1980.
25.
MosierD.E.; GuliziaR.J.; BairdS.M.; WilsonD.B.Transfer of a functional human immune system to mice with severe combined immunodeficiency.Nature335: 256–259; 1988.
26.
NishiokaY.; LipskyP.E.The role of CD40-CD40 ligand interaction in human T cell-B cell collaboration.J. Immunol.153: 1027–1036; 1994.
27.
NoelleR.J.; RoyM.; ShepherdD.M.; StamenkovicI.; LedbetterJ.A.; AruffoA.A novel ligand on activated T helper cells binds CD40 and transduces the signal for the cognate activation of B cells.Proc. Natl. Acad. Sci. USA89: 6550–6554; 1997.
28.
ParkerD.C.; GreinerD.L.; PhillipsN.E.; AppelM.C.; SteeleA.W.; DurieF.H.; NoelleR.J.; MordesJ.P.; RossiniA.A.Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand.Proc. Natl. Acad. Sci. USA92: 9560–9564; 1995.
29.
RanheimE.A.; KippsT.J.Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal.J. Exp. Med.177: 925–935; 1993.
30.
Tary-LehmannM.; LehmannP.V.; ScholsD., RoncaroloM. G.; SaxonA.Anti-SCID Mouse Reactivity Shapes the Human CD4+ T Cell Repertoire in hu-PBL-SCID Chimeras.J. Exp. Med.180: 1817–1827; 1994.
31.
TohmaS.; LipskyP.E.Analysis of the mechanisms of T cell-dependent polyclonal activation of human B cells. Induction of human B cell responses by fixed activated T cells.J. Immunol.146: 2544–2552; 1991.
32.
XuJ.; FoyT.M.; LamanJ.D.; DunnJ.J.; WaldschmidtT.J.; ElsemoreJ.; NoelleR.J.; FlavellR.A.Mice deficient for the CD40 ligand.Immunity1: 423–431; 1994.
